SGC-CBP30, a potent inhibitor of the highly selective CBP/p300 bromodomain, has shown therapeutic potential in a variety of diseases, including cancers, gastrointestinal syndromes, sepsis, and organ fibrosis62,71–73. Here, EP300 is linked to Sepsis.